Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003194 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by Seattle Children's Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00003194 is a Phase 1 study that was terminated before completion, run by Seattle Children's Hospital. The registered enrollment target is 24 participants.
The verdict
NCT00003194, a Phase 1 study, was terminated before completion, sponsored by Seattle Children's Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have recurrent or refractory solid tumors.
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG thiotepa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1997-07 |
| Est. Completion | 2002-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003194
The ClinicalTrials.gov registry entry for NCT00003194 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00003194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003194 about?
NCT00003194 is a clinical study titled "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial ...
What is the current status of trial NCT00003194?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 1997-07. Estimated completion is 2002-12-19.
What interventions are being tested in trial NCT00003194?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL), thiotepa (DRUG).
Who is sponsoring clinical trial NCT00003194?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.